Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Survival differences in transplant ineligible multiple myeloma patients in Japan and Taiwan: Exploring the potential influence of timely and unrestricted access to novel therapies

View Full Paper
Ask AI
Bookmark
Share

Authors

KSKenshi SuzukiCTChao-Hsiun TangTWTom Webb

Discussion

Loading...

Member takes

Overview

Observational analysis shows improved overall survival with daratumumab in transplant-ineligible multiple myeloma, suggesting access to novel therapies influences outcomes.

Key Points

  • Japanese patients had a survival advantage with a hazard ratio of 0.24, indicating higher overall survival than Taiwanese patients.
  • Data from over 30 million patients in Japan and relevant national health databases in Taiwan were used for analysis.
  • The study involved matching-adjusted indirect comparison analysis to account for patient characteristics and comorbidities.
  • Differential access to innovative therapies may explain the observed survival differences in transplant-ineligible multiple myeloma patients.

Cite This Study

Suzuki et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d9cehttps://doi.org/10.1182/blood-2025-4574
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Temporal trends in treatment patterns and overall survival for multiple myeloma management in Taiwan using the national health insurance claims database2025
  2. 2Improved survival in patients with multiple myeloma over time: A retrospective single-center study focusing on patients aged 80 years and above2025
  3. 3Updated analysis of survival and treatment evolution in european multiple myeloma patients (2012–2023) across 7 countries from the honeur network2025
  4. 4Racial disparities in treatment initiation and early outcomes among patients with multiple myeloma: A real-world, multi-institutional cohort study2025
  5. 5Survival outcomes of multiple myeloma patients previously exposed to BCMA-targeted therapies in the honeur european network2025